HCPCS Level II · Drugs administered other than oral method
J9019Injection, asparaginase (erwinaze), 1,000 iu
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J9019
J9019 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, asparaginase (erwinaze), 1,000 iu.
It was added to HCPCS effective 01/01/2013, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Erwinaze injection
- Date added
- 01/01/2013
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1D
Related J90xx codes
- J9000Injection, doxorubicin hydrochloride, 10 mg
- J9003Leuprolide injectable (camcevi etm), 1 mg
- J9011Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015Injection, aldesleukin, per single use vial
- J9017Injection, arsenic trioxide, 1 mg
- J9021Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022Injection, atezolizumab, 10 mg
- J9023Injection, avelumab, 10 mg
- J9024Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025Injection, azacitidine, 1 mg
- J9026Injection, tarlatamab-dlle, 1 mg
- J9027Injection, clofarabine, 1 mg
Common questions about J9019
Is HCPCS J9019 still valid?
- No. J9019 was terminated on 12/31/2025.
Does Medicare cover J9019?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.